Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Innovent
Pharma
Pfizer, Astellas, Takeda, Innovent and more—Fierce Pharma Asia
Pfizer's oncology head mused on ADC opportunities in China at this year's JPM. Astellas received a manufacturing-related rejection. Plus more.
Zoey Becker
Jan 12, 2024 8:15am
Takeda, Hutchmed hook up on cancer drug for $1.13B
Jan 23, 2023 10:31am
Coherus and Junshi's cancer immunotherapy has stalled at the FDA
May 3, 2022 8:02am
FDA oncology chief, Senate bill, Insilico—Fierce Pharma Asia
Apr 1, 2022 9:35am
FDA oncology czar defends rejection of Lilly-Innovent PD-1
Mar 28, 2022 11:34am
Trade secret suit, Lilly-Innovent, Aurobindo—Fierce Pharma Asia
Mar 25, 2022 9:00am
